Jiangxi Biological Products Research Institute Co., Ltd. (Jiangxi Bio) saw its Hong Kong stock exchange IPO prospectus expire on October 11th, six months after its initial submission on April 11th. CICC and CMB International Securities served as joint sponsors for the listing application.
According to the prospectus, citing Frost & Sullivan data, Jiangxi Bio is the largest provider of human tetanus antitoxin (TAT) in both China and globally. Based on 2024 sales volumes, the company holds market shares of 65.8% in China and 36.6% worldwide.
Tetanus antitoxin is an antiserum that provides immediate protection and treatment by neutralizing toxins produced by Clostridium tetani, the bacteria responsible for tetanus infections, thereby preventing and treating tetanus.